The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer.
Adult
Aged
Breast Neoplasms
/ genetics
Epistasis, Genetic
/ genetics
Female
GTPase-Activating Proteins
/ genetics
Gene Expression
Gene Expression Regulation, Neoplastic
/ genetics
Genotype
Humans
MicroRNAs
/ genetics
Middle Aged
Polymorphism, Single Nucleotide
RNA, Long Noncoding
/ genetics
Up-Regulation
/ genetics
Breast cancer
Genotyping
SNP
lncRNA
miRNA
Journal
Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
04
06
2020
accepted:
26
08
2020
pubmed:
4
9
2020
medline:
28
10
2020
entrez:
4
9
2020
Statut:
ppublish
Résumé
A higher expression of MALAT1 has been reported in breast cancer. However, more studies are needed to decipher the mechanisms by which this lncRNA imposes its oncogenic effects. In this study, blood and tissue samples were taken from healthy normal and breast cancer subjects. qPCR was used to analyze the gene expression. HRM-PCR method was carried out to genotype the selected samples. Computational analysis was recruited to find novel targets of MALAT1 and miR-143-3p. The data analyses revealed that MALAT1 was up-regulated in breast cancer and could be a distinctive factor to diagnose cancer. The expression of MALAT1 was inversely correlated with miR-143-3p expression in the studied clinical samples. The down-regulation of miR-143-3p was proven in the clinical tumor samples as compared to the healthy controls. A negative correlation of miR-143-3p with its putative target, RALGAPA2 was observed. A functional SNP rs3827693 located within the 3'UTR region of RALGAPA2 mRNA was validated in this study to associate with breast cancer risk. The rs3827693 allele G significantly decreased the breast cancer incidence and augmented the negative correlation between RALGAPA2 and miR-143-3p, presumably through strengthening the interaction between these two transcripts. This study proposed MALAT1 miR-143-3p and miR-143-3p RALGAPA2 axis in breast cancer, whereby the latter can be altered by the clinically functional SNP rs3827693.
Identifiants
pubmed: 32880825
doi: 10.1007/s13577-020-00422-x
pii: 10.1007/s13577-020-00422-x
doi:
Substances chimiques
GTPase-Activating Proteins
0
MALAT1 long non-coding RNA, human
0
MIRN143 microRNA, human
0
MicroRNAs
0
RALGAPA2 protein, human
0
RNA, Long Noncoding
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1229-1239Références
Espinosa E, Gámez-Pozo A, Sánchez-Navarro I, Pinto A, Castaneda C, Ciruelos E, et al. The present and future of gene profiling in breast cancer. Cancer Metastasis Rev. 2012;31(1–2):41–6.
pubmed: 22124734
doi: 10.1007/s10555-011-9327-7
Kao J, Salari K, Bocanegra M, Choi Y-L, Girard L, Gandhi J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PloS One. 2009;4(7):1–16.
doi: 10.1371/journal.pone.0006146
Van’t Veer LJ, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–6.
doi: 10.1038/415530a
van de Vijver M. Gene-expression profiling and the future of adjuvant therapy. Oncol Miamisburg. 2005;10:30.
doi: 10.1634/theoncologist.10-90002-30
Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7(1–2):4–13.
pubmed: 19574486
pmcid: 2705275
doi: 10.3121/cmr.2008.825
Van de Ven S, Smit V, Dekker T, Nortier J, Kroep J. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev. 2011;37(6):422–30.
pubmed: 21177040
Andorfer CA, Necela BM, Thompson EA, Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends Mol Med. 2011;17(6):313–9.
pubmed: 21376668
doi: 10.1016/j.molmed.2011.01.006
Shi M, Guo N. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev. 2009;35(4):328–34.
pubmed: 19171434
doi: 10.1016/j.ctrv.2008.12.002
Mashhadizadeh S, Tavangar M, Javani AF, Rahimian MD, Azadeh M, Tabatabaeian H, et al. PGR and TUG1 overexpression: a putative diagnostic biomarker in breast cancer patients. Gene Rep. 2020;21:100791.
doi: 10.1016/j.genrep.2020.100791
Balmeh N, Tabatabaeian H, Asgari M, Mokhtarian R, Abharian PH, Azadeh M, et al. miR-195 down-regulation is a distinctive biomarker of HER2 positive state in breast cancer. Gene Rep. 2020;20:100703.
doi: 10.1016/j.genrep.2020.100703
Mahdi KM, Nassiri MR, Nasiri K. Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev. 2013;14(6):3403–9.
pubmed: 23886119
doi: 10.7314/APJCP.2013.14.6.3403
DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding-Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438–51.
pubmed: 31577379
doi: 10.3322/caac.21583
Gutschner T, Hämmerle M, Diederichs S. MALAT1—a paradigm for long noncoding RNA function in cancer. J Mol Med. 2013;91(7):791–801.
pubmed: 23529762
doi: 10.1007/s00109-013-1028-y
Miao Y, Fan R, Chen L, Qian H. Clinical significance of long non-coding RNA MALAT1 expression in tissue and serum of breast cancer. Ann Clin Lab Sci. 2016;46(4):418–24.
pubmed: 27466303
Jadaliha M, Zong X, Malakar P, Ray T, Singh DK, Freier SM, et al. Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer. Oncotarget. 2016;7(26):40418.
pubmed: 27250026
pmcid: 5130017
doi: 10.18632/oncotarget.9622
Chou J, Wang B, Zheng T, Li X, Zheng L, Hu J, et al. MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42. Biochem Biophys Res Commun. 2016;472(1):262–9.
pubmed: 26926567
doi: 10.1016/j.bbrc.2016.02.102
Latorre E, Carelli S, Raimondi I, D'Agostino V, Castiglioni I, Zucal C, et al. The ribonucleic complex HuR-MALAT1 represses CD133 expression and suppresses epithelial–mesenchymal transition in breast cancer. Can Res. 2016;76(9):2626–36.
doi: 10.1158/0008-5472.CAN-15-2018
Bamodu OA, Huang W-C, Lee W-H, Wu A, Wang LS, Hsiao M, et al. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448. BMC Cancer. 2016;16(1):160.
pubmed: 26917489
pmcid: 4768424
doi: 10.1186/s12885-016-2108-5
Li J-H, Liu S, Zhou H, Qu L-H, Yang J-H. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(D1):D92–D9797.
pubmed: 24297251
doi: 10.1093/nar/gkt1248
Lánczky A, Nagy Á, Bottai G, Munkácsy G, Szabó A, Santarpia L, et al. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016;160(3):439–46.
pubmed: 27744485
doi: 10.1007/s10549-016-4013-7
Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. elife. 2015;4:e05005.
pmcid: 4532895
doi: 10.7554/eLife.05005
Gong J, Tong Y, Zhang H-M, Guo A-Y, editors. miRNASNP: a database of miRNA related SNPs and their effects on miRNA function. BMC Bioinform. 2012;13(18):1.
Sadeghi S, Hojati Z, Tabatabaeian H. Cooverexpression of EpCAM and c-myc genes in malignant breast tumours. J Genet. 2017;96(1):109–18.
pubmed: 28360395
doi: 10.1007/s12041-017-0748-0
Tabatabaeian H, Hojati Z. Assessment of HER-2 gene overexpression in Isfahan province breast cancer patients using real time RT-PCR and immunohistochemistry. Gene. 2013;531(1):39–433.
pubmed: 24013082
doi: 10.1016/j.gene.2013.08.040
Tabatabaeian S, Sadeghi S, Tabatabaeian H. PTBP1 correlates with HER2 positivity, lymph node spread and metastasis in breast cancer. Gene Rep. 2020;19:100659.
doi: 10.1016/j.genrep.2020.100659
Yu K, Toral-Barza L, Discafani C, Zhang W, Skotnicki J, Frost P, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 2001;8(3):249–58.
pubmed: 11566616
doi: 10.1677/erc.0.0080249
Gil EMC. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev. 2014;40(7):862–71.
doi: 10.1016/j.ctrv.2014.03.004
Tabatabaeian H, Rao A, Ramos A, Chu T, Sudol M, Lim YP. The emerging roles of WBP2 oncogene in human cancers. Oncogene. 2020;39:1–15.
doi: 10.1038/s41388-020-1318-0
Wellenstein MD, Coffelt SB, Duits DE, van Miltenburg MH, Slagter M, de Rink I, et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572(7770):538–42.
pubmed: 31367040
pmcid: 6707815
doi: 10.1038/s41586-019-1450-6
Golmard L, Delnatte C, Laugé A, Moncoutier V, Lefol C, Abidallah K, et al. Breast and ovarian cancer predisposition due to de novo BRCA1 and BRCA2 mutations. Oncogene. 2016;35(10):1324–7.
pubmed: 26028024
doi: 10.1038/onc.2015.181
Shamloo B, Usluer S. p21 in cancer research. Cancers. 2019;11(8):1178.
pmcid: 6721478
doi: 10.3390/cancers11081178
Ghahnavieh LE, Tabatabaeian H, Ghahnavieh ZE, Honardoost MA, Azadeh M, Bistgani MM, et al. Fluctuating expression of miR-584 in primary and high-grade gastric cancer. BMC Cancer. 2020;20(1):1–12.
doi: 10.1186/s12885-019-6169-0
Rouigari M, Dehbashi M, Tabatabaeian H, Ghaedi K, Mohammadynejad P, Azadeh M. Evaluation of the expression level and hormone receptor association of miR-126 in breast cancer. Indian J Clin Biochem. 2019;34(4):451–7.
pubmed: 31686732
doi: 10.1007/s12291-018-0766-6
Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, et al. Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis. 2017;8(9):e3045-e.
doi: 10.1038/cddis.2017.440
Adami B, Tabatabaeian H, Ghaedi K, Talebi A, Azadeh M, Dehdashtian E. miR-146a is deregulated in gastric cancer. J Cancer Res Ther. 2019;15(1):108.
pubmed: 30880764
Dehdashtian E, Tabatabaeian H, Ghaedi K, Talebi A, Adami BAH. pylori-independent miR-21 overexpression in gastric cancer patients. Gene Rep. 2019;17:100528.
doi: 10.1016/j.genrep.2019.100528
Xue X, Yang YA, Zhang A, Fong K, Kim J, Song B, et al. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene. 2016;35(21):2746–55.
pubmed: 26364613
doi: 10.1038/onc.2015.340
Xu S, Kong D, Chen Q, Ping Y, Pang D. Oncogenic long noncoding RNA landscape in breast cancer. Mol Cancer. 2017;16(1):129.
pubmed: 28738804
pmcid: 5525255
doi: 10.1186/s12943-017-0696-6
Yoshimoto R, Mayeda A, Yoshida M, Nakagawa S. MALAT1 long non-coding RNA in cancer. Biochimica et Biophysica Acta (BBA) Gene Regul Mech. 2016;1859(1):192–9.
doi: 10.1016/j.bbagrm.2015.09.012
Wang Z, Katsaros D, Biglia N, Shen Y, Fu Y, Loo LW, et al. High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival. Breast Cancer Res Treat. 2018;171(2):261–71.
pubmed: 29845475
pmcid: 6488226
doi: 10.1007/s10549-018-4839-2
Li D, Hu J, Song H, Xu H, Wu C, Zhao B, et al. miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-negative breast cancer cells. Am J Transl Res. 2017;9(5):2276.
pubmed: 28559978
pmcid: 5446510
Xia C, Yang Y, Kong F, Kong Q, Shan C. MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. Biochimie. 2018;147:98–104.
pubmed: 29360495
doi: 10.1016/j.biochi.2018.01.003
Pinweha P, Phillips CA, Gregory PA, Li X, Chuayboonya P, Mongkolsiri P, et al. MicroRNA-143-3p targets pyruvate carboxylase expression and controls proliferation and migration of MDA-MB-231 cells. Arch Biochem Biophys. 2019;677:108169.
pubmed: 31697914
doi: 10.1016/j.abb.2019.108169
Zhang Y, Wang Z, Chen M, Peng L, Wang X, Ma Q, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 2012;11(1):23.
pubmed: 22533346
pmcid: 3351020
doi: 10.1186/1476-4598-11-23
Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer. 2014;13(1):220.
pubmed: 25248370
pmcid: 4181414
doi: 10.1186/1476-4598-13-220
Ng EK, Li R, Shin VY, Siu JM, Ma ES, Kwong A. MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells. Tumor Biol. 2014;35(3):2591–8.
doi: 10.1007/s13277-013-1341-7
Bodemann BO, White MA. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer. 2008;8(2):133–40.
pubmed: 18219307
doi: 10.1038/nrc2296
Saito R, Shirakawa R, Nishiyama H, Kobayashi T, Kawato M, Kanno T, et al. Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer. Oncogene. 2013;32(7):894–902.
pubmed: 22450745
doi: 10.1038/onc.2012.101
Salimi Z, Sadeghi S, Tabatabaeian H, Ghaedi K, Fazilati M. rs11895168 C allele and the increased risk of breast cancer in Isfahan population. Breast. 2016;28:89–94.
pubmed: 27262100
doi: 10.1016/j.breast.2016.05.007
Dehghan Z, Sadeghi S, Tabatabaeian H, Ghaedi K, Azadeh M, Fazilati M, et al. ESR1 single nucleotide polymorphism rs1062577 (c.* 3804T> A) alters the susceptibility of breast cancer risk in Iranian population. Gene. 3804T;611:9–14.
pubmed: 28216037
doi: 10.1016/j.gene.2017.02.016
Zabihi N, Sadeghi S, Tabatabaeian H, Ghaedi K, Azadeh M, Fazilati M. The association between rs1972820 and the risk of breast cancer in Isfahan population. J Cancer Res Ther. 2017;13(1):26.
pubmed: 28508829
doi: 10.4103/0973-1482.183202
Moradi B, Tabatabaeian H, Sadeghi S, Azadeh M, Ghaedi K. HER4 rs1595065 3′UTR variant is a possible risk factor for HER2 positivity among breast cancer patients. Thrita. 2016;5(4):1–5.
doi: 10.5812/thrita.42195
Nabatchian F, Naiini MR, Moradi A, Tabatabaeian H, Hoghoughi N, Azadeh M, et al. miR-581-related single nucleotide polymorphism, rs2641726, located in MUC4 gene, is associated with gastric cancer incidence. Indian J Clin Biochem. 2019;34(3):347–51.
pubmed: 31391727
doi: 10.1007/s12291-018-0751-0
Bidkani MM, Tabatabaeian H, Parsafar S, Ghanei N, Fazilati M, Ghaedi K. ErbB4 receptor polymorphism 2368A> C and risk of breast cancer. Breast. 2368A;42:157–63.
doi: 10.1016/j.breast.2018.10.002
Tabatabian M, Tanha HM, Tabatabaeian H, Sadeghi S, Ghaedi K, Mohamadynejad P. ErbB4 3′-UTR variant (c.* 3622A> G) is associated with ER/PR negativity and advanced breast cancer. Indian J Clin Biochem. 3622A;35(1):115–20.
pubmed: 32071504
doi: 10.1007/s12291-018-0793-3
Samani LA, Javadirad S-M, Parsafar S, Tabatabaeian H, Ghaedi K, Azadeh M. TP53 rs1625895 is related to breast cancer incidence and early death in Iranian population. Indian J Clin Biochem. 2019;34(4):485–9.
doi: 10.1007/s12291-018-0774-6
Mokhtarian R, Tabatabaeian H, Saadatmand P, Azadeh M, Balmeh N, Yakhchali B, et al. CD44 gene rs8193 C allele is significantly enriched in gastric cancer patients. Cell J (Yakhteh). 2020;21(4):451.